Amino Acid Sequence Disclosed In Whole Or In Part; Or Conjugate, Complex, Or Fusion Protein Or Fusion Polypeptide Including The Same Patents (Class 424/185.1)
  • Patent number: 11951168
    Abstract: Provided is a composition containing a buffer to be used at the time of labeling of a chelated targeting agent with 90Y, 153Sm, 165Dy, 165Er, 166Ho, or 177Lu. At least one kind of buffer selected from the group consisting of benzoic acid, maleic acid, fumaric acid, succinic acid, and salts thereof is incorporated in a composition containing a chelated targeting agent.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: April 9, 2024
    Assignee: PERSEUS PROTEOMICS INC.
    Inventors: Yuichi Funase, Masahiro Kurokawa
  • Patent number: 11938175
    Abstract: Disclosed are yeast-based immunotherapeutic compositions comprising Brachyury antigens, and methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of Brachyury.
    Type: Grant
    Filed: December 21, 2020
    Date of Patent: March 26, 2024
    Assignees: The USA, as represented by the Secretary, Dept. of Health and Human Services, GlobeImmune, Inc.
    Inventors: Claudia Palena, Zhimin Guo, David Apelian, Jeffrey Schlom
  • Patent number: 11918626
    Abstract: Provided are compositions and methods for maintaining intestinal immune homeostasis. The method comprises administering to an individual an effective amount of a VIPR2 inhibitor. The method may modulate gut resident CCR6+ ILC3 cell function.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: March 5, 2024
    Inventors: Dan R. Littman, Jhimmy Talbot
  • Patent number: 11890350
    Abstract: Agents having cytotoxic activity, as well as compositions, uses, and methods relating thereto, are described herein. Certain steroid acid-peptide conjugates or moieties have the ability to induce killing or inhibition of proliferation of mammalian cells, in vitro or in vivo upon administration to a subject. The steroid acid-peptide conjugates include bile acids and bile acid analogs and peptides that may include a nuclear localisation signal or a portion thereof. Also described herein is a method for treating cancer, an autoimmune disease, or any other disease or disorder ameliorated by treatment with an antiproliferative drug in a subject in a subject with the cytotoxic agents described herein.
    Type: Grant
    Filed: November 16, 2022
    Date of Patent: February 6, 2024
    Assignee: DEFENCE THERAPEUTICS INC.
    Inventor: Simon Beaudoin
  • Patent number: 11883462
    Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
    Type: Grant
    Filed: May 14, 2021
    Date of Patent: January 30, 2024
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
  • Patent number: 11878057
    Abstract: Provided herein are lipid A molecules engineered from Moritella lipopolysaccharides and uses thereof.
    Type: Grant
    Filed: December 10, 2021
    Date of Patent: January 23, 2024
    Assignees: TRUSTEES OF BOSTON UNIVERSITY, THE CHILDREN'S MEDCIAL CENTER CORPORATION, MINISTRY OF FISHERIES AND MARINE RESOURCES DEVELOPMENT
    Inventors: Randi Dawn Rotjan, Anna Gauthier, Aranteiti Tekiau, Jonathan C. Kagan
  • Patent number: 11850274
    Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a WIC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: December 26, 2023
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
  • Patent number: 11839643
    Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
    Type: Grant
    Filed: May 21, 2021
    Date of Patent: December 12, 2023
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
  • Patent number: 11827921
    Abstract: This disclosure provides methods, systems, compositions, and kits for the multiplexed detection of a plurality of analytes in a sample. In some examples, this disclosure provides methods, systems, compositions, and kits wherein multiple analytes may be detected in a single sample volume by acquiring a cumulative measurement or measurements of at least one quantifiable component of a signal. In some cases, additional components of a signal, or additional signals (or components thereof) are also quantified. Each signal or component of a signal may be used to construct a coding scheme which can then be used to determine the presence or absence of any analyte.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: November 28, 2023
    Assignee: California Institute of Technology
    Inventors: Emil P. Kartalov, Aditya Rajagopal, Axel Scherer
  • Patent number: 11786489
    Abstract: Provided herein are methods, kits and compositions for the treatment and/or prevention of ovarian cancer through the induction of an immune response against Anti-Mullerian Hormone Receptor, Type II (AMHR2).
    Type: Grant
    Filed: August 17, 2021
    Date of Patent: October 17, 2023
    Assignee: The Cleveland Clinic Foundation
    Inventors: Vincent K. Tuohy, Suparna Mazumder, Justin M. Johnson
  • Patent number: 11780894
    Abstract: Disclosed herein are fusion proteins comprising a truncated thrombostasin protein having at least 85% sequence homology to a thrombostasin protein, wherein the thrombostasin protein has a carboxy terminal deletion; and a fusion partner protein that is a non-thrombostasin protein. Further disclosed are vaccine compositions thrombostasin proteins having a comprising a carboxy terminal deletion, and methods for inhibiting a response to a thrombostasin protein in a host in need thereof, comprising the disclosed fusion proteins or vaccine compositions. Further disclosed are methods for the preparation of a fusion protein composition.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: October 10, 2023
    Assignee: TNG Pharmaceuticals, Inc.
    Inventors: Kent R. Van Kampen, Serge Martinod
  • Patent number: 11767355
    Abstract: The present disclosure provides methods of modulating an immune response in an individual. The present disclosure provides methods of treatment. The present disclosure provides methods comprising administering a multimeric polypeptide (synTac) and an immune checkpoint inhibitor to an individual. The present disclosure provides methods comprising administering a multimeric polypeptide (synTac) to an individual who is undergoing treatment with immune checkpoint inhibitor.
    Type: Grant
    Filed: October 6, 2022
    Date of Patent: September 26, 2023
    Assignee: Cue Biopharma, Inc.
    Inventors: Ronald D. Seidel, III, Rodolfo J. Chaparro
  • Patent number: 11759509
    Abstract: A compound represented by the formula (1): wherein Xa and Ya are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R1 is a hydrogen atom, a group represented by the formula (2): wherein Xb and Yb are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: September 19, 2023
    Assignees: Sumitomo Pharma Co., Ltd., INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
    Inventors: Chiang Jia Li, Hitoshi Ban, Yukihiro Nishio, Masashi Goto, Toshio Nishihara, Yosuke Takanashi
  • Patent number: 11725035
    Abstract: Compounds capable of mimicking the pyrin-domain of IF116 is provided together with compounds capable of binding to the pyrin-domain of IF116 or a fragment thereof as well as their uses in medicine. Specifically, the compounds are provided for use in the treatment of disorders associated with STING activity, including cancer and immuno-deficient or auto-immune disorders.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: August 15, 2023
    Assignee: STipe Therapeutics ApS
    Inventors: Martin Roelsgaard Jakobsen, Søren Riis Paludan, Kasper Lisager Jønsson
  • Patent number: 11679153
    Abstract: The present invention relates to methods for inducing an immune response, in particular methods for adjuvanting the immune response to an antigen comprising the separate administration of a saponin and a TLR4 agonist.
    Type: Grant
    Filed: November 27, 2020
    Date of Patent: June 20, 2023
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Margherita Coccia, Arnauld Michel Didierlaurent
  • Patent number: 11673937
    Abstract: The present invention relates to a chimeric receptor capable of signaling both a primary and a co-stimulatory pathway, thus allowing activation of the co-stimulatory pathway without binding to the natural ligand. The cytoplasmic domain of the receptor contains a portion of the 4-1BB signaling domain. Embodiments of the invention relate to polynucleotides that encode the receptor, vectors and host cells encoding a chimeric receptor, particularly including T cells and natural killer (NK) cells and methods of use.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: June 13, 2023
    Assignee: St. Jude Children's Research Hospital, Inc.
    Inventors: Dario Campana, Chihaya Imai
  • Patent number: 11654190
    Abstract: The disclosure provides synthetic (e.g. recombinant) pneumococcal saccharide comprising one or more repeat unit(s) ?4)-?-D-Glcp-(1?3)-[[?-L-Rhap-(1?2)]-[Gro-(2?P?3)]-?-D-Galp-(1?4)]-?-L-Rhap-(1?. Also provided are conjugates comprising a ?4)-?-D-Glcp-(1?3)-[[?-L-Rhap-(1?2)]-[Gro-(2?P?3)]-?-D-Galp-(1?4)]-?-L-Rhap-(1?, immunogenic compositions, vaccines and their use in preventing or treating infection by Streptococcus pneumoniae.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: May 23, 2023
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Amirreza Faridmoayer, Rainer Follador, Stefan Jochen Kemmler, Michael Thomas Kowarik, Gerd Martin Lipowsky, Gerald Johann Posch, Fabio Serventi
  • Patent number: 11639368
    Abstract: A peptide is described, which consists of 7-17 adjacent amino acids and comprises the hexamer TXEXXE, wherein X, X and X can be any natural or non-natural amino acid, wherein the peptide has no TNF receptor binding activity and is cyclized, for the prevention and treatment of hyperpermeability of epithelial cells and endothelial cells.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: May 2, 2023
    Assignee: APEPTICO FORSCHUNG UND ENTWICKLUNG GMBH
    Inventors: Bernhard Fischer, Rudolf Lucas
  • Patent number: 11571461
    Abstract: The present invention relates to the use of a CD24 protein for treating Systemic Lupus Erythematosus (Lupus, SLE).
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: February 7, 2023
    Assignee: ONCOIMMUNE, INC.
    Inventors: Yang Liu, Pan Zheng, Martin Devenport
  • Patent number: 11564944
    Abstract: Contemplated compositions and methods generate a durable immune synapse and so lead to activated T-cells and memory T-cell formation by use of selected co-stimulatory receptors and their ligands in conjunction with selected neoepitopes. Moreover, immune competent cells are attracted into a tumor microenvironment after activation of the T-cells using hybrid or chimeric binding proteins that comprise a chemokine portion and that target components of necrotic cells.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: January 31, 2023
    Assignee: Nant Holdings IP, LLC
    Inventor: Patrick Soon-Shiong
  • Patent number: 11559589
    Abstract: Compositions and methods are provided for inhibiting T cell mediated destruction of virally transduced, trangene containing cells.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: January 24, 2023
    Assignee: The Children's Hospital of Philadelphia
    Inventors: Katherine A. High, Marcela V. Maus, Federico Mingozzi, Daniel J. Hui
  • Patent number: 11542316
    Abstract: The present invention relates to a composition which comprises peptides derived from S-Arrestin (retinal arrestin, S-antigen, S-Ag). The composition or peptides may be useful in the prevention and/or suppression of S-Ag autoimmunity, which is useful in the treatment and/or prevention of uveitis.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: January 3, 2023
    Assignee: Worg Pharmaceuticals (Zhejiang) Co., Ltd.
    Inventors: David Wraith, Evelien Schurgers, Keith Martin, Liselotte Jansson
  • Patent number: 11505599
    Abstract: The presently disclosed subject matter provides antigen-binding proteins (e.g., chimeric antigen receptors) and antibodies or antigen-binding portions thereof that bind to a Foxp3 peptide/MHC molecule complex. Such antibodies, fusion proteins and conjugates thereof are useful for inhibiting regulatory T cells and treating cancers.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: November 22, 2022
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
    Inventors: David A. Scheinberg, Tao Dao, Cheng Liu
  • Patent number: 11492387
    Abstract: The use of an HLA-G molecule and its antigenic fragments prepared a broad spectrum vaccine which could be used to prevent the invasion of various tumors and various viruses or unknown virus on human and animal body.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: November 8, 2022
    Assignee: Tianjin Dongya Biological Technology Co., Ltd.
    Inventor: Dianjie Su
  • Patent number: 11485767
    Abstract: This invention provides methods and materials for treating cancer. The invention encompasses methods and materials for delivering programmed death-ligand 1 (PD-L1) binding compounds and/or compositions containing one or more monovalent or multivalent programmed death-ligand 1 (PD-L1) binding compounds which are administered to a mammal having cancer to treat the mammal. In some cases, a multivalent PD-L1 binding compound can include two or more programmed cell death protein 1 (PD-1) polypeptides (and/or fragments thereof having the ability to bind PD-L1). This invention also provides methods and materials for making multivalent PD-L1 binding compounds and methods and materials for making nucleic acid molecules that encode PD-L1 binding compounds.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: November 1, 2022
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventor: Michael A. Barry
  • Patent number: 11472862
    Abstract: The invention relates to a peptide comprising the amino acid sequence SEQ ID NO: 1 or a variant thereof capable of inhibiting IL13/IL13R?2 signalling. The invention also relates to a fusion protein, nanoparticle, virus-like particle and pharmaceutical composition comprising said peptide, and to their use for treating a cancer characterized by having increased expression of IL13R?2, or for treating asthma, atopic dermatitis or fibrosis, or for preventing the metastatic progression of a cancer characterized by having increased expression of IL13R?2.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: October 18, 2022
    Assignee: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS
    Inventors: Jose Ignacio Casal Alvarez, Rubén Álvaro Bartolomé Conde
  • Patent number: 11472860
    Abstract: In a first aspect, provided herein are chimeric antigen receptors (CAR) composed of at least an extracellular domain, a transmembrane domain and an intracellular domain, the extracellular domain comprises a spacer domain located C-terminally to a ligand-binding-domain also present in the extracellular domain, whereby the spacer domain comprises at least part of the CD34 molecule. Also provided are nucleic acid molecules encoding the same as well as vectors and cells containing the same. The cells include engineered T-cells and NK-cells and derivatives thereof. A pharmaceutical composition comprising the CAR e.g. in form of a vector, a polynucleotide encoding the CAR or the CAR itself and, in addition, cells, cell lines or host cells accordingly are provided. The CAR is useful in adoptive cell therapy. Finally, a method for enrichment or purification of CAR, in particular, of genetically engineered cells, cell lines or host cells expressing the CAR is provided.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: October 18, 2022
    Assignees: WESTFAELISCH-WILHELMS-UNIVERSITAET, HEINRICH-HEINE-UNIVERSITAET DUSSELFDORF
    Inventors: Claudia Roessig, Helmut Hanenberg, Constanze Wiek, Tabea Ibach, Katharina Roellecke
  • Patent number: 11446369
    Abstract: The present invention provides KLK3 peptides, FOLH1 peptides, recombinant polypeptides comprising same, recombinant nucleotide molecules encoding same, recombinant Listeria strains comprising same, and immunogenic and therapeutic methods utilizing same.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: September 20, 2022
    Assignees: ADVAXIS, INC., THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Yvonne Paterson, John Rothman, Vafa Shahabi
  • Patent number: 11447569
    Abstract: Provided are anti-PAD4 antibodies having excellent properties and an excellent method for treatment of RA. Used are anti-PAD4 antibodies that specifically bind to an epitope containing positions 345, 347, and 348 of PAD4. These anti-PAD4 antibodies may inhibit the citrullination activity of PAD4. In addition, these anti-PAD4 antibodies may have a KD (M) of 9.0×10?9 or less. Optionally, the anti-PAD4 antibody and a TNF? inhibitor are used in combination.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: September 20, 2022
    Assignees: PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY, PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY, PHARMA FOODS INTERNATIONAL CO., LTD.
    Inventors: Mamoru Sato, Michiyuki Yamada, Satoshi Kanazawa, Masayoshi Toyoura, Yuji Shoya, Kenji Saito, Chihiro Yamazaki
  • Patent number: 11400114
    Abstract: Uniform, functional polymer patches can be attached to a fraction of the surface area of living individual cells. These surface-modified cells can cross the blood-brain barrier while remaining viable after attachment of the functional patch. Functional payloads carried by the patch can include a drug. The patch can include one or more polyelectrolyte multilayers (PEMs).
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: August 2, 2022
    Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
    Inventors: Roberta Polak, Robert E. Cohen, Michael F. Rubner, Elena V. Batrakova, Matthew J. Haney, Natalia L. Klyachko, Yuling Zhao
  • Patent number: 11389546
    Abstract: mRNAs containing an exogenous open reading frame (ORF) flanked by a 5? untranslated region (UTR) and a 3? UTR is provided, wherein the 5? and 3? UTRs are derived from a naturally abundant mRNA in a tissue. Also provided are methods for identifying the 5? and 3? UTRs, and methods for making and using the mRNAs.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: July 19, 2022
    Assignee: ModernaTX, Inc.
    Inventors: David H. Burkhardt, Romesh R. Subramanian, Christian Cobaugh
  • Patent number: 11384119
    Abstract: Methods and compositions for inhibiting and/or interfering with interactions between (1) programmed Death-1 protein (also known as CD279) and (2) programmed death-ligand 1 (PD-L1) and/or programmed death-ligand 2 (PD-L2) are disclosed. In addition, methods and compositions for increasing IL-2 levels in a cell, and methods and compositions for preventing, treating, or ameliorating the effects of cancer in a subject, are disclosed.
    Type: Grant
    Filed: March 2, 2020
    Date of Patent: July 12, 2022
    Inventors: William Jia, Xuexian Bu, I-Fang Lee
  • Patent number: 11384156
    Abstract: A chimeric antigen receptor specific for the extracellular membrane-proximal domain (EMPD) of membrane-bound IgE (mIgE) is provided. The EMPD-specific chimeric antigen receptor comprises an extracellular ligand binding domain capable of binding EMPD, a transmembrane domain, and an intracellular domain that mediates T cell activation upon EMPD binding. Nucleic acids and vectors encoding the EMPD-specific chimeric antigen receptor are provided. T cells transduced with such vectors find use in chimeric antigen receptor-based adoptive T-cell therapy for targeting IgE-expressing B cells and treating IgE-mediated allergic diseases.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: July 12, 2022
    Assignee: THE NEMOURS FOUNDATION
    Inventor: Zhengyu Ma
  • Patent number: 11376323
    Abstract: The disclosure describes compositions containing PEGylated compounds using linkers, bivalent polysaccharide covalent PEG compounds, and methods of bivalent polysaccharide-PEG compounds in the development of multivalent vaccines. PEGylated conjugation of capsular polysaccharides to carrier proteins is carried out using homo-bifunctional and/or hetero-bifunctional linkers of specific lengths. Incorporation of bifunctional PEG linkers induces higher titers of functional antibodies with high avidity, eliciting higher immunologic memory, and reduced carrier protein effect. This provides immunochemically cross-reactive capsular polysaccharides wherein one or more cross-reactive capsular polysaccharides are covalently PEG compounded sequentially or concurrently to carrier protein using bifunctional linkers bearing the same or different functional groups.
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: July 5, 2022
    Assignee: Inventprise, LLC
    Inventors: Subhash V. Kapre, Anup K. Datta
  • Patent number: 11369569
    Abstract: Isolated peptides targeting cardiovascular disease are described herein or one or more conservative amino acid substitutions, deletions or additions of such peptides and methods of use thereof for delivering payloads to specific cell types or tissues.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: June 28, 2022
    Assignee: University of Virginia Patent Foundation
    Inventors: Alexander L. Klibanov, Brent A. French, Kimberly A. Kelly, Siva Sai Krishna Dasa
  • Patent number: 11359014
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-5 protein, e.g., human Siglec-5 or a mammalian Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: June 14, 2022
    Assignee: Alector LLC
    Inventors: Kate Monroe, Helen Lam, Patricia Culp, Arnon Rosenthal
  • Patent number: 11345731
    Abstract: The present invention provides Claudin-6-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: May 31, 2022
    Assignees: BioNTech Cell & Gene Therapies GmbH, TRON-Translationale Onkologie An Der Universitatsmedzin Der Johannes Gutenberg-Universitat Mainz, Ganymed Pharmaceuticals AG
    Inventors: Ugur Sahin, Özlem Türeci, Petra Simon, Tana Omokoko, Holger Hoff, Ralf-Holger Voss, Andrea Breitkreuz, Kathleen Hobohm, Karolina Anna Mroz
  • Patent number: 11339443
    Abstract: A method for detecting genes sensitive to low-level ionizing radiation and genes detected by the method. More specifically, genes sensitive to low-level ionizing radiation and related to suppressing thymic cancer, discovered in a carcinogenic entity and verified in a normal entity are detected by subjecting a cancerous AKR/J mouse and a normal ICR mouse to low-level radiation. Thymus is collected therefrom, immunogenic and apoptotic genes are classified via microarray processing of the thymus. The genes are amplified and the levels of gene expression are measured. Thus, a gene having a specific reaction to radiation can be accurately detected by preventing the interference of confounding variables.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: May 24, 2022
    Assignee: KOREA HYDRO & NUCLEAR POWER CO., LTD.
    Inventors: Hee Sun Kim, Seung Jin Choi, Moo Hyun Choi, Jin Jong Bong, Seok Cheol Shin
  • Patent number: 11311598
    Abstract: Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: April 26, 2022
    Assignee: Soligenix, Inc.
    Inventors: Oreola Donini, Annett Rozek, Jackson Lee, John North, Michael Abrams
  • Patent number: 11298404
    Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a WIC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
    Type: Grant
    Filed: October 1, 2021
    Date of Patent: April 12, 2022
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
  • Patent number: 11291718
    Abstract: The present invention provides a medicine comprising a Toll-like receptor agonist, LAG-3 protein, a variant or derivative thereof.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: April 5, 2022
    Assignee: CYTLIMIC INC.
    Inventors: Tomoya Miyakawa, Shun Doi, Koji Tamada
  • Patent number: 11273200
    Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
    Type: Grant
    Filed: September 24, 2021
    Date of Patent: March 15, 2022
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
  • Patent number: 11266708
    Abstract: The present invention relates to novel formulations of soluble Fc receptors and especially to formulations containing high concentrations of soluble Fc?RIIB receptor. The invention further relates to the use of such formulations as pharmaceutical compounds for the treatment of autoimmune diseases, infections and other conditions where the immune system is involved.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: March 8, 2022
    Assignee: SUPPREMOL GMBH
    Inventors: Peter Sondermann, Thomas Pohl
  • Patent number: 11260010
    Abstract: The present invention relates to cochleates using phosphatidylserine/anionic surfactant/calcium chloride and, more specifically, to cochleates comprising phosphatidylserine, an anionic surfactant, calcium chloride, an active ingredient, and water.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: March 1, 2022
    Assignee: H&A PHARMACHEM CO., LTD
    Inventors: Hong Geun Ji, Hae In Choi, Young Ah Park, Yu Jin Kang
  • Patent number: 11254915
    Abstract: Provided is a method for separating and extracting mesenchymal stem cells from the human umbilical cord. The method uses healthy neonatal umbilical cord tissue; after cleaning and disinfection, mechanically pulverising same, separating the Wharton's jelly, and after treating with erythrocyte lysate, carrying out suspension culture in a serum-free culture medium. Replacing the liquid every 3-5 days; after the plate adherence rate reaches 30-70%, carrying out trypsin digestion, and then collecting the cells by centrifugation for passage amplification, until the rate of confluence of the cells reaches 80-90% confluence, thereby obtaining high purity umbilical cord mesenchymal stem cells.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: February 22, 2022
    Inventors: Lei Guo, Cheng Li
  • Patent number: 11246890
    Abstract: Mesenchymal stromal cells are engineered to express a chimeric antigen receptor (CAR), that specifically binds a marker of activated myeloid cells, including without limitation folate receptor beta; and are administered to an individual for treatment of inflammation at sites characterized by the presence of activated myeloid cells.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: February 15, 2022
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Tzuhua Dennis Lin, Stuart B. Goodman, Sai-Wen Tang, Everett Hurteau Meyer, Magdiel Pérez Cruz
  • Patent number: 11246942
    Abstract: Antibodies and meditopes that bind to the antibodies are provided, as well as complexes, compositions and combinations containing the meditopes and antibodies, and methods of producing, using, testing, and screening the same, including therapeutic and diagnostic methods and uses.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: February 15, 2022
    Assignee: City of Hope
    Inventors: John C. Williams, David A. Horne, Yuelong Ma, Heng Wei Chang, Joshua Michael Donaldson, Cindy Zer, Krzysztof Bzymek, Kendra Nicole Avery, Jun Xie
  • Patent number: 11246943
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: February 15, 2022
    Assignee: École Polytechnique Fédérale de Lausanne (EPFL)
    Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
  • Patent number: 11248213
    Abstract: Provided herein are cytoplasts, compositions comprising cytoplasts, methods of using cytoplasts, and methods of treating a subject, such as providing benefits to a healthy or unhealthy subject, or treating or diagnosing a disease or condition in a subject. In some embodiments, methods of treating a subject include: administering to the subject a therapeutically effective amount of a composition comprising a cytoplast. Also, provided herein are compositions (e.g., pharmaceutical compositions) that include a cytoplast. Also, provided herein are kits comprising instructions for using the compositions or methods.
    Type: Grant
    Filed: January 27, 2021
    Date of Patent: February 15, 2022
    Assignee: The Regents of the University of California
    Inventors: Richard Klemke, Huawei Wang
  • Patent number: 11241482
    Abstract: The present invention provides for methods and compositions for treating or preventing arthritis and joint injury.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: February 8, 2022
    Assignees: NOVARTIS AG, The Scripps Research Institute
    Inventors: Lori Jennings, Kristen Johnson, Peter Schultz